30 closest matches · ranked by relevance
Colorectal Cancer · Metastatic Cancer
Primary: 2 Year Disease-free Survival . — 9 percentage of participants
Liver Neoplasms · Hepatectomy
Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL
Liver Resection · Cancer
Primary: Changes in Liver Remnant Volume — 18.4; 80.7 percentage change
Hepatobiliary Disease
Primary: The Total Blood Loss — 376.73; 339.81 ml
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
Carcinoma, Hepatocellular
Primary: Successful Insertion of Ablation Antenna Into Target Lesion — 100 percentage of participants
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
Liver Cancer
Primary: Proportion of Participants With Successful Control of Disease at 18 Months — .18 proportion of participants
Liver Transection During Laparoscopic Liver Resection
Primary: Intraoperative Blood Loss — 195; 218 ml
Hepatocellular Carcinoma
Primary: Number of Participants With Local Tumor Response According to mRECIST — 26; 0; 0; 3 Participants
Tissue Donors · Liver Transplantation · Ischemia Reperfusion Injury
Primary: Postopera The Maximal Aspartate Aminotransferase Level Within 7 Postoperative Days — 145; 152 IU/L
Hepatocellular Carcinoma · Resectable Hepatocellular Carcinoma
Primary: Safety and Tolerability of Presurgical Nivolumab With or Without Ipilimumab, Defined as the Number of Participants With of Adverse Events. — 13; 14; 0 Participants
Colorectal Cancer
Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
Liver Cancer
Primary: CO Output (Ppm) — 2.03 ppm
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
Adult Hepatocellular Carcinoma · Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma
Primary: Severe Treatment-related Toxicity — 0 Participants
Liver Cancer
Primary: Neovessel Formation as Measured by Angiogram at 14 Weeks — 2; 3 participants
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Postoperative Hemorrhage
Primary: Time to Hemostasis — 2.2; 4.4 minutes — p=0.004
Liver Metastases
Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events
Complication, Postoperative
Primary: Complications, Post-anesthesia Care Unit (PACU) — 51; 58 Participants — p=0.213
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 4-minutes Following Randomization — 48; 24 participants with hemostatic success — p=<.0001
Bariatric Surgery Candidate · Hiatal Hernia
Primary: Number of Device Related Adverse Events — 0 Device related adverse events
Liver Cancer
Primary: Median Overall Survival — 31.1 months